Grundläggande statistik
| CIK | 1601830 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Recursion Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| May 6, 2026 |
rxrx1q2026earningspresen Earnings 1Q26 MAY 6, 2026 This presentation of Recursion Pharmaceuticals, Inc. |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commis |
|
| May 6, 2026 |
Recursion Reports First Quarter Financial Results and Provides Business Update Exhibit 99.1 Recursion Reports First Quarter Financial Results and Provides Business Update •Multiple milestones achieved or on track across wholly owned and partnered programs •REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable, dose-dependent pharmacokinetics; no DLTs observed to date, supporting ongoing dose escalation •REC |
|
| April 30, 2026 |
Recursion Announces Board Transition Exhibit 99.1 Recursion Announces Board Transition SALT LAKE CITY, Utah, April 30, 2026 — Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June 2026 and does not intend to seek re-election to the Company’s Board of Directors. “I greatly appreciated Chris’s |
|
| April 30, 2026 |
A Letter from Our CEO Dear Shareholders, 2025 marked an important inflection point for Recursion — the year our AI-native foundation began translating from theoretical advantage into clinical reality. |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2026 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| March 25, 2026 |
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer Exhibit 99.1 Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer SALT LAKE CITY, Utah, March 25, 2026 at 8:00 am ET (GLOBE NEWSWIRE) – Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026 as David Mauro, M. |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2026 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| February 25, 2026 |
ye25earningsdeckfinal This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “potential,” “predicts, |
|
| February 25, 2026 |
RECURSION PHARMACEUTICALS, INC. SALES AGREEMENT Exhibit 10.35 RECURSION PHARMACEUTICALS, INC. $300,000,000 SALES AGREEMENT February 25, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Recursion Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to |
|
| February 25, 2026 |
RECURSION PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Exhibit 10.13 RECURSION PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Recursion Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Di |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026 Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation or |
|
| February 25, 2026 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Recursion Pharmaceuticals, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Class A common stock, par value $0.00001 per share. As used in this summary, the terms “Recursion,” “the Company |
|
| February 25, 2026 |
Confirmatory Employment Letter Exhibit 10.19 December 2, 2024 David Hallet Confirmatory Employment Letter Dear David: Exscientia AI Ltd. (the “Company,” “we,” “us,” or “our”), a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (“Recursion”) is truly excited to extend you an offer on the terms and conditions in this letter agreement (the “Agreement”) and to confirm you will continue with us in our mission of decoding b |
|
| February 25, 2026 |
Exhibit 10.16 November 5, 2025 Najat Khan, Ph.D. c/o Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 Re: CEO Employment Terms Dear Najat: This letter agreement (the “Agreement”) is entered into between the undersigned (“you”) and Recursion Pharmaceuticals, Inc. (the “Company” or “we”) and set forth the terms of your employment as the Company’s President and Chief Ex |
|
| February 25, 2026 |
Exhibit 10.14 ADVISORY AGREEMENT This Advisory Agreement (this “Agreement”) is effective as of January 1, 2026 (the “Effective Date”) by and between Recursion Pharmaceuticals, Inc. (the “Company”), and Christopher Gibson (“Advisor”) (each herein referred to individually as a “Party,” or collectively as the “Parties”). 1.SERVICES AND COMPENSATION 2.Advisor shall serve in the role of Advisor to the |
|
| February 25, 2026 |
Up to $300,000,000 Recursion Pharmaceuticals, Inc. Class A Common Stock PROSPECTUS SUPPLEMENT (To prospectus dated February 12, 2025) Up to $300,000,000 Recursion Pharmaceuticals, Inc. |
|
| February 25, 2026 |
As filed with the Securities and Exchange Commission on February 25, 2026 As filed with the Securities and Exchange Commission on February 25, 2026 Registration No. |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 Recursion Phar |
|
| February 25, 2026 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| February 25, 2026 |
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Exhibit 99.1 Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update •Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing with defined milestones •Achieved fifth program mi |
|
| February 25, 2026 |
Exhibit 19.1 RECURSION PHARMACEUTICALS, INC. INSIDER TRADING POLICY (Adopted on March 19, 2021; most recently amended October 23, 2025) A.POLICY OVERVIEW Recursion Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading |
|
| February 25, 2026 |
Exhibit 21.1 List of Subsidiaries The following is a list of subsidiaries of Recursion Pharmaceuticals Inc. as of December 31, 2025. Name of Subsidiary* Jurisdiction of Incorporation Exscientia Limited United Kingdom Exscientia (UK) Holdings Ltd. United Kingdom Exscientia AI Ltd. Scotland Kinetic Discovery Ltd Scotland Exscientia Inc. Delaware Exscientia Ventures I Inc. Delaware RE Ventures I LLC |
|
| February 25, 2026 |
Exhibit 107 Filed Pursuant to Rule 424(b)(5) Registration No. 333-284878 Calculation of Filing Fee Tables S-3 (Form Type) Recursion Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| January 12, 2026 |
recursionjpm2026presenta JANUARY 2026 NAJAT KHAN, PHD CEO & PRESIDENT, RECURSION Recursion JP Morgan Presentation NK 25-Dec-25: Would move supercomputer image here NK 25-Dec-25: And a patient image – lets redo the design to make it fresh! Maintaining ambition while raising the bar NK 29-Dec-25: NEW – NK COMMENTS This presentation of Recursion Pharmaceuticals, Inc. |
|
| December 8, 2025 |
fapdecember2025webinarde Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy December 8, 2025 This presentation discusses an investigational product whose safety and efficacy have not been established. |
|
| December 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| December 8, 2025 |
Exhibit 99.1 Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks ●REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) ●After 12 weeks off therapy |
|
| November 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| November 26, 2025 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 . PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2025) Recursion Pharmaceuticals, Inc. Up to 7,088,742 Shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the proposed resale or other disposition from time to time of up to 7,088,742 shares of our Class A Common Stock, or the Sh |
|
| November 26, 2025 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 Calculation of Filing Fee Tables S-3 (Form Type) Recursion Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECUR |
|
| November 5, 2025 |
a3q2025corporatepresenta Decoding Biology To Radically Improve Lives November 2025 - Corporate Presentation This presentation of Recursion Pharmaceuticals, Inc. |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| November 5, 2025 |
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update •Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological diseases •With this achievement, Recursion will have reached over $500 million in milestone and u |
|
| November 5, 2025 |
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth Exhibit 99.2 Recursion Announces CEO Transition Plan to Drive Next Phase of Growth Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan, to be named Chief Executive Officer and President SALT LAKE CITY, November 5, 2025 – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Di |
|
| November 5, 2025 |
a3q2025learningsdeckweb 2Q25 (L)earnings August 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| October 10, 2025 |
144 0001856369 XXXXXXXX LIVE 0001601830 RECURSION PHARMACEUTICALS, INC. 001-40323 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203 Gibson Christopher Officer Director Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 100000 604000.00 427312960 10/10/2025 NASDAQ Class A 09/01/2016 Founders Shares Issuer N 100000 09/01/2016 Compensation N Christopher C. Gibson |
|
| September 25, 2025 |
144 0001856369 XXXXXXXX LIVE 0001601830 RECURSION PHARMACEUTICALS, INC. 001-40323 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203 Gibson Christopher Officer Director Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 100000 476000.00 427312960 09/25/2025 NASDAQ Class A 09/01/2016 Founders Shares Issuer N 100000 09/01/2016 Compensation N Christopher C. Gibson |
|
| September 10, 2025 |
144 0001856369 XXXXXXXX LIVE 0001601830 RECURSION PHARMACEUTICALS, INC. 001-40323 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203 Gibson Christopher Officer Director Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 100000 471000.00 427312960 09/10/2025 NASDAQ Class A 09/01/2016 Founders Shares Issuer N 100000 09/01/2016 Compensation N Christopher C. Gibson |
|
| August 29, 2025 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 Calculation of Filing Fee Tables S-3 (Form Type) Recursion Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| August 29, 2025 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 . PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2025) Recursion Pharmaceuticals, Inc. Up to 2,397,023 Shares of Class A Common Stock Offered by the Selling Stockholder We are registering the proposed resale or other disposition from time to time of up to 2,397,023 shares of our Class A Common Stock, par value $0.00001 per share |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| August 5, 2025 |
corporatepresentationau Corporate Deck August 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| August 5, 2025 |
q22025earningsdeck 2Q25 (L)earnings August 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| August 5, 2025 |
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, August 5, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biolog |
|
| July 8, 2025 |
Recursion Acquires Full Rights to REV102, a Potential Exhibit 99.1 Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia SALT LAKE CITY, July 8, 2025 – Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an assoc |
|
| July 8, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 RECURSION PHARMACEUTICALS, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Eff |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commi |
|
| July 8, 2025 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2025) Recursion Pharmaceuticals, Inc. Up to 1,457,952 Shares of Class A Common Stock Offered by the Selling Stockholder We are registering the proposed resale or other disposition from time to time of up to 1,457,952 shares of our Class A Common Stock, par value $0.00001 per share ( |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| June 10, 2025 |
EX-99.1 Exhibit 99.1 Corporate Deck June 2025 Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects |
|
| May 9, 2025 |
424B7 Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2025) Recursion Pharmaceuticals, Inc. Up to 4,260,927 Shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the proposed resale or other disposition from time to time of up to 4,260,927 shares of our Class A Common Stock, or th |
|
| May 9, 2025 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount registered Proposed maximum offering price per Unit (2) |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commis |
|
| May 5, 2025 |
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Recursion Reports First Quarter 2025 Financial Results and Provides Business Update •Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 pre-clinical program following a strategic, data-driven review •Partnerships: A |
|
| May 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| May 5, 2025 |
As filed with the Securities and Exchange Commission on May 5, 2025 As filed with the Securities and Exchange Commission on May 5, 2025 Registration No. |
|
| May 5, 2025 |
q12025learningsdeck 1Q25 (L)earnings MAY 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commis |
|
| April 28, 2025 |
2024 Annual Report 2024 Annual ReportA Letter from Our Co-Founder and CEO Dear Shareholders, As we step into 2025, I want to take a moment to reflect on where Recursion stands today and where we are headed. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 18, 2025 |
Recursion Pharmaceuticals, Inc. Outside Director Compensation Policy EXHIBIT 10.1 RECURSION PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Recursion Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Dir |
|
| March 18, 2025 |
EXHIBIT 99.1 Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy. SALT LAKE CITY, Mar 18, 2025 (GLOBE NEWSWIRE) - Recursion (N |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| February 28, 2025 |
Recursion Pharmaceuticals, Inc. Insider Trading Policy. Exhibit 19.1 RECURSION PHARMACEUTICALS, INC. INSIDER TRADING POLICY (Adopted on March 19, 2021; most recently amended April 27, 2023) A.POLICY OVERVIEW Recursion Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in |
|
| February 28, 2025 |
Global Access Commitments Agreement between the Registrant and the Bill & Melinda Gates Foundation. Exhibit 4.8 Certain information in this document, marked by brackets [****], has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. Global Access Commitments Agreement This Global Access Commitments Agreement (including |
|
| February 28, 2025 |
Separation Agreement between the Registrant and Michael Secora. Exhibit 10.20 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Michael Secora (“Employee”) and Recursion Pharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee is employed at will by the Company; WHEREAS, the Company granted Employee the option(s) to pur |
|
| February 28, 2025 |
Exhibit 10.39 SALES AGREEMENT February 28, 2025 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: Recursion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Citigroup Global Markets Inc., as sales agent and/or principal (the “Agent”) |
|
| February 28, 2025 |
Exhibit 21.1 List of Subsidiaries The following is a list of subsidiaries of Recursion Pharmaceuticals Inc. as of December 31, 2024. Name of Subsidiary* Jurisdiction of Incorporation Exscientia Limited United Kingdom Exscientia (UK) Holdings Ltd. United Kingdom Exscientia AI Ltd. Scotland Kinetic Discovery Ltd Scotland Exscientia Inc. Delaware Exscientia Ventures I Inc. Delaware RE Ventures I LLC |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 Recursion Phar |
|
| February 28, 2025 |
rxrxlearnings10k2024 Forward-looking statements 2 This presentation of Recursion Pharmaceuticals, Inc. |
|
| February 28, 2025 |
EXHIBIT 10.36 EXECUTION VERSION RESEARCH COLLABORATION AGREEMENT dated September 19, 2023 by and between EXSCIENTIA AI LTD. and MERCK HEALTHCARE KGAA Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. RESEARCH COLLABORATION AGREEMENT This Resea |
|
| February 28, 2025 |
Exhibit 99.1 Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results •Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous malformations •Advanced three new clinical studies across oncology, rare disease, a |
|
| February 28, 2025 |
Transition Agreement between the Registrant and Tina Marriott. Exhibit 10.18 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between Tina Marriott (“Employee”) and Recursion Pharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee is employed at will by the Company; WHEREAS, the Company granted Employee the option(s |
|
| February 28, 2025 |
Exhibit 10.35 EXECUTION VERSION Certain information in this document, marked by brackets [****], has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. RESEARCH COLLABORATION AND LICENCE OPTION AGREEMENT BETWEEN: Sanofi |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation or |
|
| February 28, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Recursion Pharmaceuticals, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Class A common stock, par value $0.00001 per share. As used in this summary, the terms “Recursion,” “the Company |
|
| February 28, 2025 |
rxrx2025corporatedeck Decoding Biology To Radically Improve Lives FEBRUARY 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| February 28, 2025 |
Exhibit 107 Filed Pursuant to Rule 424(b)(5) Registration No. 333-284878 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount registered Proposed maximum offering price per Unit Max |
|
| February 28, 2025 |
Confirmatory Employment Letter between the Registrant and Ben Taylor. December 2, 2024 Ben Taylor Confirmatory Employment Letter Dear Ben: Exscientia AI Ltd. |
|
| February 28, 2025 |
Recursion Pharmaceuticals, Inc. Up to $500,000,000 Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-284878 PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2025) Recursion Pharmaceuticals, Inc. Up to $500,000,000 Class A Common Stock We entered into a Sales Agreement, dated February 28, 2025, or the sales agreement, with Citigroup Global Markets Inc., or Citigroup, relating to the sale of shares of our Class A Common Stock, par value $ |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedu |
|
| February 12, 2025 |
Exhibit 4.9 RECURSION PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establ |
|
| February 12, 2025 |
As filed with the Securities and Exchange Commission on February 12, 2025 S-3ASR As filed with the Securities and Exchange Commission on February 12, 2025 Registration No. |
|
| February 12, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| February 5, 2025 |
EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Life Limited BlackRock Advisors, LLC Aperio Group, LLC BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. BlackRock Japan Co., Ltd. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC BlackRock Investment Management (UK) Limited SpiderRock A |
|
| February 5, 2025 |
EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| January 13, 2025 |
Decoding Biology to Radically Improve Lives JANUARY 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| December 17, 2024 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 . PROSPECTUS SUPPLEMENT (to Prospectus dated May 10, 2022) Recursion Pharmaceuticals, Inc. Up to 3,498,393 Shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the proposed resale or other disposition from time to time of up to 3,498,393 shares of our Class A Common Stock, or the Shares, |
|
| December 17, 2024 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Amount to be registered(1) Proposed |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| November 27, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On August 8, 2024, Recursion Pharmaceuticals, Inc. (“Recursion”) entered into a transaction agreement (the “Transaction Agreement”), as amended by the First Amendment to the Transaction Agreement dated as of November 5, 2024 (the “First Amendment”), with Exscientia plc (“Exscientia”) to acquire the entire issued and to be is |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 RECURSION PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40323 46-4099738 (State or Other Jurisdiction |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| November 20, 2024 |
exhibit992-closingdeck NOVEMBER 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| November 20, 2024 |
Plan and forms of agreement thereunder. Exhibit 4.6 RECURSION PHARMACEUTICALS, INC. 2024 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nons |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| November 20, 2024 |
As filed with the Securities and Exchange Commission on November 20, 2024 As filed with the Securities and Exchange Commission on November 20, 2024 Registration No. |
|
| November 20, 2024 |
Three months ended September 30, Exhibit 99.4 Exscientia plc Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive (Loss)/Income for the three and nine months ended September 30, 2024 and 2023 Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Note £’000 £’000 £’000 £’000 Revenue 4 4,930 8,882 14,639 17,649 Cost of sales (7,530) (6,742) (22,696) (21,468) Gross (loss |
|
| November 20, 2024 |
EXHIBIT 99.3 Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery ●Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs ●Platform will focus on first and best-in-class drug di |
|
| November 20, 2024 |
Exscientia plc 2021 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan Exhibit 4.5 EXSCIENTIA PLC 2021 EQUITY INCENTIVE PLAN WITH NON-EMPLOYEE SUB-PLAN AND CSOP SUB-PLAN ADOPTED BY THE BOARD OF DIRECTORS: 11 AUGUST 2021 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: 23 AUGUST 2021 SHARE RESERVE APPROVED BY THE PRICING COMMITTEE OF THE BOARD OF DIRECTORS: [DATE] 2021 IPO DATE: [DATE] 2021 APPROVED BY THE SHAREHOLDERS: [DATE] 2021 TABLE OF CONTENTS Page 1. PURPOSE 1 2 |
|
| November 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| November 20, 2024 |
The Exscientia Unapproved Share Option Plan with RSU Sub-Plan Exhibit 4.4 The Exscientia Unapproved Share Option Plan Plan Rules Adopted by the Board on 13th February 2018 and amended on 25th September 2019 and 1st April 2021 Plan Rules Definitions 1.1 In these Rules (and, where applicable, any Option Agreement) the following words and expressions shall have the following meanings: “Acting in Concert” the meaning given in the City Code on Takeovers and Merge |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 (November 12, 2024) RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction |
|
| November 13, 2024 |
Recursion and Exscientia Shareholders Approve the Proposed Combination EXHIBIT 99.1 Recursion and Exscientia Shareholders Approve the Proposed Combination ●Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Salt Lake City, Utah, and Oxford, UK, November 13, 2024: Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and |
|
| November 12, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GRecursionP.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* (Name of Issuer) Recursion Pharmaceuticals Inc (Title of Clas |
|
| November 12, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 RECURSION PHARMACEUTICALS INC CLASS A COMMON STOCK Cusip #75629V104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75629V104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,359,174 Item 6: 0 Item 7: 8,363,529 |
|
| November 8, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us75629v1044110824.txt us75629v1044110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) RECURSION PHARMACEUTICALS, INC. - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 75629V104 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Che |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 6, 2024 (November 5, 2024) Date of Report (date of earliest event reported) RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of |
|
| November 6, 2024 |
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results Exhibit 99.1 Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results •Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and IND clearance for a Phase 1/2 trial in biomarker-enriched solid tumors and lymphoma (Target RBM39), whi |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECUR |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| November 6, 2024 |
November 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| November 6, 2024 |
Exhibit 2.1 EXECUTION VERSION FIRST AMENDMENT TO TRANSACTION AGREEMENT This first Amendment TO THE TRANSACTION AGREEMENT (this “Amendment”), dated as of November 5, 2024, is by and between Recursion Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and Exscientia plc, a public limited company incorporated in England and Wales with registered number 13483814 (the “Company”). WHEREAS, Parent |
|
| November 4, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / Kinnevik AB (publ) - SC 13G/A Passive Investment SC 13G/A 1 tm2427110d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Recursion Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.00001 per share (Title of Class of Securities) 75629V104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing |
|
| November 4, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GRecursionP.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Recursion Pharmaceuticals Inc (Title of Clas |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| October 22, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / BlackRock, Inc. Passive Investment us75629v1044102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) RECURSION PHARMACEUTICALS, INC. - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 75629V104 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| October 18, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 RecursionPharmaInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RECURSION PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 75629V104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r |
|
| October 10, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Co |
|
| October 2, 2024 |
EXHIBIT 99.1 Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma ●First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months ●Plan to initiate dosing of Phase 1/ |
|
| October 2, 2024 |
rxrx2024q2corp October 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| September 17, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| September 17, 2024 |
Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 686,475,441. |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| September 3, 2024 |
Investor Presentation of Recursion Pharmaceuticals, Inc. dated September 3, 2024. September 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| September 3, 2024 |
exhibit991-rxrxsept2024 September 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| September 3, 2024 |
Press Release of Recursion Pharmaceuticals, Inc. dated September 3, 2024. Exhibit 99.2 Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the pote |
|
| September 3, 2024 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.3 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 876) F-2 Consolidated Statement of Loss and Other Comprehensive Loss F-3 Consolidated Statement of Financial Position F-4 Consolidated Statement of Changes in Equity F-6 Consolidated Statement of Cash Flows F-8 Notes to the Financial Statements F-10 F-1 Report of Independ |
|
| September 3, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.5 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On August 8, 2024, Recursion Pharmaceuticals, Inc. (“Recursion”) entered into a transaction agreement (the “Transaction Agreement”) with Exscientia plc (“Exscientia”) to acquire the entire issued and to be issued share capital of Exscientia pursuant to a scheme of arrangement (the “Scheme of Arrangement”) under Part 26 of th |
|
| September 3, 2024 |
Exhibit 99.3 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 876) F-2 Consolidated Statement of Loss and Other Comprehensive Loss F-3 Consolidated Statement of Financial Position F-4 Consolidated Statement of Changes in Equity F-6 Consolidated Statement of Cash Flows F-8 Notes to the Financial Statements F-10 F-1 Report of Independ |
|
| September 3, 2024 |
Exhibit 99.4 Exscientia plc Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Note £’000 £’000 £’000 £’000 Revenue 4 4,419 3,006 9,709 8,767 Cost of sales (7,759) (6,269) (15,166) (14,726) Gross loss (3,340) (3,263) (5,457) (5,9 |
|
| September 3, 2024 |
Exhibit 99.5 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On August 8, 2024, Recursion Pharmaceuticals, Inc. (“Recursion”) entered into a transaction agreement (the “Transaction Agreement”) with Exscientia plc (“Exscientia”) to acquire the entire issued and to be issued share capital of Exscientia pursuant to a scheme of arrangement (the “Scheme of Arrangement”) under Part 26 of th |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| September 3, 2024 |
Exhibit 99.4 Exscientia plc Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Note £’000 £’000 £’000 £’000 Revenue 4 4,419 3,006 9,709 8,767 Cost of sales (7,759) (6,269) (15,166) (14,726) Gross loss (3,340) (3,263) (5,457) (5,9 |
|
| September 3, 2024 |
Exhibit 99.2 Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the pote |
|
| August 28, 2024 |
Irrevocable Undertaking of Evotec SE dated August 28, 2024. Exhibit 10.1 INSTITUTIONAL SHAREHOLDER IRREVOCABLE UNDERTAKING To: Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 United States ("Parent") Exscientia plc The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom (the "Company") August 28, 2024 Dear Sir/Madam Proposed acquisition of the Company 1.ACQUISITION 1.1In this deed of undertaking (the "Unde |
|
| August 28, 2024 |
Irrevocable Undertaking of Evotec SE dated August 28, 2024. Exhibit 10.1 INSTITUTIONAL SHAREHOLDER IRREVOCABLE UNDERTAKING To: Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 United States ("Parent") Exscientia plc The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom (the "Company") August 28, 2024 Dear Sir/Madam Proposed acquisition of the Company 1.ACQUISITION 1.1In this deed of undertaking (the "Unde |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Co |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Co |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| August 8, 2024 |
Form of Irrevocable Undertaking (Individual). EX-10.3 EXHIBIT 10.3 INDIVIDUAL SHAREHOLDER IRREVOCABLE UNDERTAKING To: Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 United States (“Parent”) Exscientia plc The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom (the “Company”) August 8, 2024 Dear Sir/Madam Proposed acquisition of the Company 1. ACQUISITION 1.1 In this undertaking (the “Undert |
|
| August 8, 2024 |
EX-99.2 EXHIBIT 99.2 Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results • Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilities • Recursion expects 7 clinical trial readouts for itself over the next 18 months and approximately 10 c |
|
| August 8, 2024 |
EX-99.4 Exhibit 99.4 Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “p |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| August 8, 2024 |
EX-99.3 Exhibit 99.3 Decoding Biology To Radically Improve Lives August 2024 Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “b |
|
| August 8, 2024 |
Form of Irrevocable Undertaking (Institutional). EX-10.2 EXHIBIT 10.2 INSTITUTIONAL SHAREHOLDER IRREVOCABLE UNDERTAKING To: Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 United States (“Parent”) Exscientia plc The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom (the “Company”) August 8, 2024 Dear Sir/Madam Proposed acquisition of the Company 1. ACQUISITION 1.1 In this undertaking (the “Und |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| August 8, 2024 |
EX-99.1 EXHIBIT 99.1 Recursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities • Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug |
|
| August 8, 2024 |
EX-2.1 EXHIBIT 2.1 TRANSACTION AGREEMENT by and between EXSCIENTIA PLC and RECURSION PHARMACEUTICALS, INC. Dated as of August 8, 2024 TABLE OF CONTENTS Page ARTICLE I THE TRANSACTION 2 Section 1.01 The Transaction 2 Section 1.02 Closing 2 Section 1.03 Delivery of Court Order 2 ARTICLE II TRANSFER OF SCHEME SHARES; DELIVERY OF EXCHANGE SHARES 3 Section 2.01 Transfer of Scheme Shares 3 Section 2.02 |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| August 8, 2024 |
Form of Voting and Support Agreement. EX-10.1 EXHIBIT 10.1 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (as the same may be amended from time to time in accordance with its terms, this “Agreement”), dated as of August 8, 2024, by and between the undersigned stockholder (the “Stockholder”) in such person’s capacity as a stockholder of Recursion Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and Exscientia p |
|
| August 8, 2024 |
Employment Offer Letter, dated July 1, 2024, between the Registrant and Dr. Najat Khan, Ph.D. EXHIBIT 10.1 41 S. Rio Grande Street Salt Lake City, Utah 84101 (385) 269-0203 recursionpharma.com July 1, 2024 Najat Khan, Ph.D. Re: Employment Offer Letter Dear Najat: Recursion Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) is truly excited to extend you an offer on the terms and conditions in this letter agreement (the “Agreement”) and hope that you will be joining us in our missi |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| July 8, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Recursion Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.00001 per share (Title of Class of Securities) 75629V104 (CUSIP Number) June 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| June 27, 2024 |
30,769,230 Shares Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 PROSPECTUS SUPPLEMENT (to Prospectus dated May 10, 2022) 30,769,230 Shares Class A Common Stock We are offering 30,769,230 shares of our Class A common stock, $0.00001 par value per share, or Class A Common Stock, in this offering. Our Class A Common Stock is listed on the Nasdaq Global Select Market under the symbol “RXRX.” On June 26, |
|
| June 27, 2024 |
Exhibit 1.1 Recursion Pharmaceuticals, Inc. 30,769,230 Shares of Class A Common Stock, $0.00001 par value Underwriting Agreement June 26, 2024 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC, As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282 c/o J.P. Morgan Securities LLC 383 M |
|
| June 27, 2024 |
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock Exhibit 99.2 Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock SALT LAKE CITY, UT - June 26, 2024 - Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock |
|
| June 27, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| June 27, 2024 |
Exhibit 107 Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(5)(1) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount reg |
|
| June 27, 2024 |
Recursion Announces Proposed Offering of Class A Common Stock Exhibit 99.1 Recursion Announces Proposed Offering of Class A Common Stock SALT LAKE CITY, Utah – June 26, 2024 – Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offe |
|
| June 26, 2024 |
Subject to Completion, Dated June 26, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| June 24, 2024 |
downloadday2024pdf AGENDA PLACEHOLDER Morning Session 9:30 am – 12:30 pm Afternoon Session 1:30 pm – 4:30 pm Welcome State of Recursion Chris Gibson PhD – Co-Founder & CEO Recursion OS Lina Nilsson PhD – Senior VP of Inception Labs Preclinical Laura Schaevitz PhD – Senior VP and Head of Research Fireside Chat with Deepak Nijhawan, MD, PhD David Mauro MD PhD – Chief Medical Officer Deepak Nijhawan |
|
| June 24, 2024 |
Exhibit 99.1 Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Its Download Day ●Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination ●Bayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discov |
|
| June 13, 2024 |
United States securities and exchange commission logo June 13, 2024 Christopher Gibson Chief Executive Officer and Director Recursion Pharmaceuticals, Inc. |
|
| June 13, 2024 |
June 13, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attn: Mary Mast Ibolya Ignat Re: Recursion Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 29, 2024 File No. 001-40323 Ladies and Gentlemen: Recursion Pharmaceuticals, Inc. (“Recursion,” “we |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commi |
|
| May 30, 2024 |
United States securities and exchange commission logo May 30, 2024 Christopher Gibson Chief Executive Officer and Director Recursion Pharmaceuticals, Inc. |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commi |
|
| May 24, 2024 |
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board Exhibit 99.1 Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur SALT LAKE CITY, US (May 24, 2024) – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| May 9, 2024 |
rxrx2024q1website Decoding Biology To Radically Improve Lives May 2024 Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| May 9, 2024 |
Letter dated May 9, 2024, from Ernst & Young LLP to the Securities Exchange Commission. Exhibit 16.1 May 9, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated May 9, 2024, of Recursion Pharmaceuticals, Inc. and are in agreement with the statements contained in the first, fourth, fifth, sixth and seventh paragraphs and the second sentence of the second paragraph on pages two and three therein. We have |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| May 9, 2024 |
rxrxlearningsq22024 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| May 9, 2024 |
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results Exhibit 99.1 Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results •On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024 •Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will support the construction of foundation models across biology, chemistry, and patient outcomes •Tra |
|
| May 9, 2024 |
Advisory Agreement between the Registrant and Shafique Virani EXHIBIT 10.1 ADVISORY AGREEMENT This Advisory Agreement (this “Agreement”) is made and entered into as of February 6, 2024 (the “Effective Date”) by and between Recursion Pharmaceuticals, Inc., (the “Company”), and Shafique Virani (“Advisor”) (each herein referred to individually as a “Party,” or collectively as the “Parties”). 1.SERVICES AND COMPENSATION Advisor shall perform the services describ |
|
| May 9, 2024 |
Transition Agreement between the Registrant and Shafique Virani EXHIBIT 10.2 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between Shafique Virani (“Employee”) and Recursion Pharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed a confirmatory employment lette |
|
| April 23, 2024 |
7BXggXeYebEhe 9b&bhaWXeTaW9;E [l]ollhniljlimj]ncpmb[lbif^l) N]olmcih]fl[n^cnmnhnb[hhcplm[lsch/-/0)[h^[mEl f]n[]eihnbj[mn^][^iocf^cha[h^fiieilq[l^nin bhrn ^][^)cnfmch]l[mchafs]f[lnb[nq[lchnbgc^mni [nlgh^iomn]bhifias[h^=E*^lcphnl[hmcncihchiolmi]cns+ Ghiqf^aqilelm[lihnbjl]cjc]i[g[mmcpnl[hmilg[n cihchnbclqile8go]binbnicfg^^^chninbjli]mmm ) msmngm[h^^fcplsni^[sqcffacpq[snibcablc]ch]s)gil]l[ncpcns[h^mg[ |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 16, 2024 |
Exhibit 99.1 Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors SALT LAKE CITY, April 16th, 2024- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| February 29, 2024 |
Recursion Pharmaceuticals, Inc. Compensation Recovery Policy RECURSION PHARMACEUTICALS, INC. COMPENSATION RECOVERY POLICY As adopted on October 31, 2023 Recursion Pharmaceuticals, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay |
|
| February 29, 2024 |
Exhibit 21.1 List of Subsidiaries The following is a list of subsidiaries of Recursion Pharmaceuticals Inc. as of December 31, 2023. Name of Subsidiary* Jurisdiction of Incorporation Recursion Pharmaceuticals Canada, Inc. Canada Valence Discovery Inc. Canada Valence Discovery USA, Inc. Delaware Cyclica Therapeutics Inc. Canada Cyclica Ltd. United Kingdom Cyclica Inc. Delaware Giro Health Inc. Dela |
|
| February 29, 2024 |
Exhibit 10.21 CERTAIN INFORMATION, MARKED BY BRACKETS AND ASTERISKS (I.E., [***]), HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amended and Restated Research Collaboration and Option Agreement by and between Bayer AG and Recursion Pharmaceuticals, Inc. TABLE OF CONTENTS Chapter A – Introduc |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 Recursion Phar |
|
| February 29, 2024 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Recursion Pharmaceuticals, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Class A common stock, par value $0.00001 per share. As used in this summary, the terms “Recursion,” “the Company |
|
| February 27, 2024 |
rxrx2023q4website Decoding Biology To Radically Improve Lives February 2024 Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| February 27, 2024 |
rxrx2023q4learningsfilin Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| February 27, 2024 |
Exhibit 99.1 Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results •Multiple clinical programs from Recursion's first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the near-term •In-licensed a program (Target Epsilon) that emerged from our fibrosis collab |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation or |
|
| February 13, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Recursion Pharmaceuticals, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 75629V104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245872d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Recursion Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 75629V104 (CUSIP Number) January 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 9, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.0 RECURSION PHARMACEUTICALS INC CLASS A COMMON STOCK Cusip #75629V104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75629V104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 10,894,689 Item 6: 0 Item 7: 10,897,286 Item 8: 0 Item 9: 1 |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| January 31, 2024 |
Amended and Restated Bylaws of Recursion Pharmaceuticals, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF RECURSION PHARMACEUTICALS, INC. (initially adopted on September 1, 2016) (as amended on January 25, 2024) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| January 29, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / ARK Investment Management LLC - SC 13G Passive Investment SC 13G 1 tm244117d2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Recursion Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 75629V104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 29, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment us75629v1044012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) RECURSION PHARMACEUTICALS, INC. - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 75629V104 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 26, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / BAILLIE GIFFORD & CO Passive Investment SC 13G/A 1 recursionpharma29122023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 RECURSION PHARMACEUTICALS, INC. (Amendment no.3) - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 75629V104 - (CUSIP Number) 29 December 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| January 24, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING RECURSION PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 75629V104 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHE |
|
| January 8, 2024 |
January 2024 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Co |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| December 20, 2023 |
rxrx2023q3decwebsite Decoding Biology To Radically Improve Lives December 2023 2 Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| December 20, 2023 |
Exhibit 99.1 Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. Kyiv, Ukraine/Salt Lake City, US: Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industr |
|
| December 15, 2023 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Amount to be registered(1) Proposed |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| December 15, 2023 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 . PROSPECTUS SUPPLEMENT (to Prospectus dated May 10, 2022) Recursion Pharmaceuticals, Inc. Up to 3,225,902 Shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the proposed resale or other disposition from time to time of up to 3,225,902 shares of our Class A Common Stock, or the Shares, |
|
| November 9, 2023 |
Exhibit 99.2 Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA and Updated Focus of Collaboration with Bayer to Precision Oncology With additional patient centric data, compute power and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio. SALT LAKE CITY, November 9, 2023 — Recursion ( |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECUR |
|
| November 9, 2023 |
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results Exhibit 99.1 Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results •Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI models together with Recursion's proprietary data and for designing biomarker and patient stratification strategies for clinical programs •Expansion |
|
| November 9, 2023 |
Decoding Biology To Radically Improve Lives End of Q3 2023 2 Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| November 9, 2023 |
Master Agreement between the Company and Tempus Labs, Inc dated November 3, 2023 Exhibit 10.4 CERTAIN INFORMATION, MARKED BY BRACKETS AND ASTERISKS [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Master Agreement This Master Agreement (inclusive of all Exhibits and Order Forms, the “Agreement”) is entered into by and between Tempus Labs, Inc. (on behalf of itself an |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| October 2, 2023 |
Decoding Biology To Radically Improve Lives Early October 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) |
|
| September 5, 2023 |
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection Exhibit 99.1 Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection ●REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events ●Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024 SALT LAKE CITY, September 5, 2023 - Recursion (NASDAQ: |
|
| September 5, 2023 |
rxrx2023sepwebsite Decoding Biology To Radically Improve Lives Early September, 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of |
|
| August 8, 2023 |
Employment Offer Letter, dated May 19, 2023, between the Registrant and Dr. David Mauro, M.D., Ph.D. 41 S. Rio Grande Street Salt Lake City, Utah 84101 (385) 269-0203 recursionpharma.com May 19, 2023 David Mauro Re: Employment Offer Letter Dear David: Recursion Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) is truly excited to extend you an offer on the terms and conditions in this letter agreement (the “Agreement”) and hope that you will be joining us in our mission of decoding biol |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| August 8, 2023 |
Exhibit 107 Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Amount to be registered Proposed ma |
|
| August 8, 2023 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Amount to be registered(1) Proposed |
|
| August 8, 2023 |
Open Market Sales Agreement dated August 8, 2023 by and between the Registrant and Jefferies LLC Exhibit 10.6 OPEN MARKET SALES AGREEMENT1 August 8, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Recursion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s |
